- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04190992
E-Based Technology to Provide Decision Aid on Breast Reconstruction for Women With Breast Cance
December 5, 2019 updated by: Su-Ying Fang, National Cheng-Kung University Hospital
The Effect of E-Based Technology to Provide Personalized Decision Aid on Breast Reconstruction for Women With Breast Cancer
Using decision aids has been demonstrated to support women to make treatment decision effectively.
However, these studies focused on the decision of receiving breast conservative surgery or mastectomy, had short term follow-ups on decision satisfaction.The aims of this study were: Evaluate the effect of E-based & personalized breast reconstruction surgery decision aid on women's decision satisfaction and mental health.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Randomized controlled trial will be used to examine the effect of E-based & personalized breast reconstruction surgery decision aid on decision satisfaction, body image, anxiety and depression.
Participants will be randomly assigned into either experimental or control groups with 88 women in each group.
After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a E-based & personalized breast reconstruction surgery decision aid at clinic.
Control group will only receive pamphlet and usual care.
All participants will be followed up 1 week after consultation, and 1 month, 8 month and 12 month after surgery.
Study Type
Interventional
Enrollment (Anticipated)
176
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tainan, Taiwan
- National Cheng Kung University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- age of at least 20 years or under 20 years but married
- females newly diagnosed with breast cancer who are candidates for mastectomy
- ability to read and speak Taiwanese or Mandarin
Exclusion Criteria:
- Women with cancer recurrence
- poor cognitive function
- diagnosed with psychiatric disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Application (APP) group
After completing the questionnaires at baseline, participants in the experimental group will be asked to receive a pamphlet and an E-based & personalized breast reconstruction surgery decision aid at clinic.
|
This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
Other Names:
A pamphlet introduce the introduction of types of surgery
|
|
Other: Usual care group
After completing the questionnaires at baseline, participants in the control group will only receive a pamphlet as usual care
|
A pamphlet introduce the introduction of types of surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body image
Time Frame: Pre-surgery, 1 month, 8 month, 12 month post surgery
|
The Body Image Scale (BIS) has ten items rated on a four-point Likert scale (0 [not at all] to 3 [very much]), with total scores ranging from 0 to 30.
Higher scores indicate greater BI distress.
|
Pre-surgery, 1 month, 8 month, 12 month post surgery
|
|
Decision Regret
Time Frame: 1 month, 8 month, 12 month post surgery
|
Decision Regret Scale (DRS) accesses "distress or remorse after a surgery decision".
This instrument contains 5 items.
The items were summed, divided by 5, and multiplied by 25.
Higher scores indicate greater decision regret.
|
1 month, 8 month, 12 month post surgery
|
|
Decision conflict
Time Frame: Pre-surgery, 1 week after intervention
|
Decision Conflict Scale (DCS) accesses the perception of uncertainty in information, values or support for surgery options.
This instrument contains 16 items and was developed by O'Connor.
The items were summed, divided by 16, and multiplied by 25.
Higher scores indicate greater decision conflict.
|
Pre-surgery, 1 week after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety
Time Frame: Pre-surgery, 1 month, 8 month, 12 month post surgery
|
The Hospital Anxiety and Depression Scale (HADS) assesses symptoms of anxiety and depression.
The HADS includes 14 items, of which 7 measure anxiety, and 7 measure depression.
All items are scored using a 0-3 point scale, with higher scores indicating more depressive symptoms.
Cut-off scores are used to categorize anxiety and depressive symptoms, with values of over 8 indicating possible anxiety and depression, and 11 or above indicating probable anxiety.
|
Pre-surgery, 1 month, 8 month, 12 month post surgery
|
|
Depression
Time Frame: Pre-surgery, 1 month, 8 month, 12 month post surgery
|
The Hospital Anxiety and Depression Scale (HADS) assesses symptoms of anxiety and depression.
The HADS includes 14 items, of which 7 measure anxiety, and 7 measure depression.
All items are scored using a 0-3 point scale, with higher scores indicating more depressive symptoms.
Cut-off scores are used to categorize anxiety and depressive symptoms, with values of over 8 indicating possible anxiety and depression, and 11 or above indicating probable depression.
|
Pre-surgery, 1 month, 8 month, 12 month post surgery
|
|
Involvement in the Breast Reconstruction (BR) decision-making process scale
Time Frame: 1 week after intervention
|
Involvement in the BR decision-making process was divided into two subscales, one accesses the perception of medical information about surgery obtained with 6 items and the other assesses the perception of partners' involvement in the BR decision-making process with 7 items.
The scale used a five-point Likert scale (1 [strongly disagree] to 5 [strongly agree]); the higher the score, the greater the amount of information the participants believed they had obtained and the greater the participants perceived their partner's involvement in the BR decision-making process.
|
1 week after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Su-Ying Fang, PhD, National Cheng Kung University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2017
Primary Completion (Actual)
July 25, 2019
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
December 4, 2019
First Submitted That Met QC Criteria
December 5, 2019
First Posted (Actual)
December 9, 2019
Study Record Updates
Last Update Posted (Actual)
December 9, 2019
Last Update Submitted That Met QC Criteria
December 5, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-ER-106-072
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on E-based & personalized breast reconstruction surgery decision aid
-
The Netherlands Cancer InstituteUMC Utrecht; Dutch Cancer SocietyCompletedBreast CancerNetherlands
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States
-
Agency for Healthcare Research and Quality (AHRQ)Completed
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedBreast Cancer | SurgeryUnited States
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedIntimate Partner ViolenceUnited States
-
Dartmouth-Hitchcock Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsEnrolling by invitationGender Dysphoria | Transgender Persons | Transsexualism | Transgenderism | Gender Incongruence | Phalloplasty | Gender Dysphoria, AdultUnited States
-
National Institute of Oncology, HungaryRecruitingQuality of Life | Breast Cancer | Patient Satisfaction | Mastectomy; LymphedemaHungary
-
Xijing HospitalRecruitingBreast Cancer | Breast ReconstructionChina